The presentation discusses the Dutch clusters showcased at the TCI Global Conference 2016, emphasizing a collaborative approach to addressing societal challenges through various sectors, including green economy and life sciences. Pivot Park, a significant innovative drug discovery facility, fosters a community of R&D companies and emphasizes open innovation by providing state-of-the-art resources for research and development. The document highlights the contributions and financials of projects aimed at strengthening the regional economic profile and promoting collaborations between academia and industry.

1. Titel presentatie
[Naam, organisatienaam]
Working Day - Track: Modern cluster policy
Dutch clusters on stage
Ingrid Coninx, Hans Rijnten, Mirjam Mol & James Wilson
Dutch clusters on stage

2. Dutch Clusters on Stage
Ingrid Coninx, Wageningen Environmental Research
Hans Rijnten, Economic Board Utrecht
Mirjam Mol, Pivot Park
James Wilson, Orkestra – Basque Institute of
Competitiveness

3. Large variety
3

4. TCI GLOBAL CONFERENCE 2016
Dutch clusters on the stage
Hans Rijnten, Economic Board Utrecht
November 10, 2016

5. Megatrend 1: Climate Change

6. Megatrend 2: Ageing population

7. Megatrend 3: Digitalisation

8. Economic Board Utrecht
Economic Research – our strenghts

9. Economic Board Utrecht
Triple helix partners

10. • Societal challenge = economic
opportunity
• Strategic agenda:
o green economy
o Life sciences & health
o Service innovation
• Private commitment (businesses)
• Scalable
• Reinforcement profile region
Economic Board Utrecht
Regional agenda 2013-2020: Green, Healthy and Smart

11. EBU: Results 2015
Initiatief Bijdrage Vorm Omvang Spin off €
NOM; 033-Energy € 1,4 M Cofin. € 5 M € 90 M
Fiware € 0.94 M Cofin. € 2.64 M € 20 M
Dutch Game Garden € 0.750 M Cofin. € 2.25 M € 20 M
DGA - Control conference € 0.15 M Cofin. € 0.95 M € 2 M
‘Groen-gezond-slim’ fund € 1 M lening € 4 M PM.
NOMMIF € 0.55 M Cofin. € 0.675 M € 7,2 M
MIT-regelingen € 1 M Cofin. € 2 M € 6 M
Totaal € 5,8 M variabel € 17,5 M € 145 M

12. www.pivotpark.com
Pivot Park
The ecosystem
Mirjam Mol
10 November 2016

13. ● 13
Pivot Park is a unique park in the Netherlands
THE place for innovative drug
discovery research and development in
the Netherlands: form target to market
Where chemistry and biology meet
Turn key facilities: state of the art
laboratories, offices, completely
furnished and equipped to start
research or development activities
Unique core facilities:
Modern equipment which is needed for
biological, chemical and analytical lab
research
two pilot plants
ultra high throughput screening facility with
compound collection
R & D services (equipment / utilities /
waste management) by a team of
experts; customized solution for our
customers

14. History

15. Analytic
s
HTS
uHTS
Compou
nds
Pilot
Plant
s
Lab &
Office
facilities
• Fully equipped
labs
• Open Access
labs
• Flex labs
• Nuclear
Magnetic
Resonance
• Liquid
Chromatograph
y
• Mass
Spectrometry
• Open Access
HTS
• Flexible uHTS
• Hit / Lead
optimization
• Up to 10 kg
• GMP standard
• Small
Unieke faciliteiten, apparatuur, kennis en
bedrijfsvoering

16. Growth of the Pivot Park Community

17. Pivot Park community (September 2016)
CROs
Product
developm
ent
CMOs
Other
service
s

18. Pivot Park community – R&D pathway
(September 2016)
Acerta Pharma
APO-T
Aduro Biotech Europe
Glycostem
InnatOss
Lead Pharma
Litevax
Modiquest
NTRC
Osteo-Pharma
SynAffix
Productdevelopment
3D-PharmXchange
CRO
AUTHOR!
BioAxis
BioXpert
InProcess-LSP
Pivot Park Screening Centre
Spinnovation Analytical
Quality by Design
Quantitative Solutions
Quintiles
Zwiers Regulatory
CRO
Aspen
CMO
BioConnection
ChemConnection
CMO
Arnold+Siedsma BAMInfra Strukton
Otherservices
Bogaerts en Groenen CVIS Thema groep
Dotcombusiness ESP Van Oss Groep
Friday Life Sciences Hulshof Kroonen & Groen
Ekoy Investment Partners Rescop
Otherservices
RegistrationTarget
discovery
Lead
discovery
Lead
optimization
Pre-clinical
development
Clinical
phase I
Clinical
phase II
Clinical
phase III
Large
scale
manufacturing

19. Pivot Park Community
Benefits of the ecosystem
• Inspiration by interaction
• New opportunities for
collaboration
• Diversity: from target to
market
• Sharing high-end
facilities = cost reduction
• Strong position in
regional, national and
international knowledge
infrastructure

20. Main trend in innovative entrepreneurship worldwide!
Facilitating open innovation
Closed
innovatio
n
Open
innovatio
n
From closed …
• Solo-creation
• Transactions
• IP legal drive
• Academic research
funding by
industry
• Large enterprises
determine market
access for
innovation
… to open
innovation:
• Co-creation
• Networks/Relations
hips
• Entrepreneurial
drive
• Commercial &
Academic research
collaboration
• SMEs accelerate
market access in
innovation

21. Screening consortia
TKI Oncodrugs
Target
ID
HTS
Hit
Optimisation
Lead
Optimisation
Development
Candidate
Clinical
Development
Identification and development of compounds for different targets
• NKI, NTRC, Covalution BioSciences and Lead Pharma  targets
• PPSC  High Throughput Screening using their compound library
• Leids Instituut voor Chemie (LIC)  MedChem (in close collaboration with PPSC)
• NKI  testing
• Lead Pharma, Covalution BioSciences and NTRC  MedChem, H2L and LO
Objective: Find lead series/clinical candidates in the field of oncology and interest
from big pharma
Covalution BioSciences